PMA device
Frontier and Frontier II Families of Pacemakers
Abbott Medical · Pulse Generator, Pacemaker, Implantable, With Cardiac Resynchronization (Crt-P) (NKE, Class III) · First FDA decision Apr 29, 2005, newest Apr 4, 2008Heart failure
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
17
Naming "Frontier"
MAUDE reports
0
Brand "Frontier", since 2015
PubMed studies
24,492
Mentioning "Frontier"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Frontier and Frontier II Families of Pacemakers
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 4 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy System (WiSE CRT)National analysisReview closedCAG-00471NUpdated Nov 18, 2026
- Cardiac Pacemakers: Single-Chamber and Dual-Chamber Permanent Cardiac PacemakersNational analysisReview closedCAG-00063R3Updated Sep 17, 2026
- Cardiac PacemakersNational analysisReview closedCAG-00063R2Updated Sep 14, 2026
- Cardiac PacemakersNational analysisReview closedCAG-00063RUpdated Sep 14, 2026
- Cardiac PacemakersNational analysisReview closedCAG-00063NUpdated Sep 14, 2026
- Single Chamber and Dual Chamber Permanent Cardiac PacemakersNational determinationOn the books20.8.3Updated Dec 2, 2024
- Cardiac PacemakersNational determinationOn the books20.8Updated Aug 16, 2023
- Anesthesia in Cardiac Pacemaker SurgeryNational determinationOn the books10.6Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Frontier", any status and sponsor, newest update first.
Mayo ClinicAcademic, hospital or other
NCT07772817 · 15 participants (planned) · Start Jun 1, 2026 · Primary completion Apr 23, 2027
Device: Frontier X Plus chest-strap ECG device; MoMe ARC ambulatory ECG monitor · For: Cardiac Arrhythmia
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
Boston Scientific CorporationPublic (BSX)
NCT05303467 · 36 participants (planned) · Start Jul 30, 2022 · Primary completion Jan 31, 2027
Device: TheraSphere GBM · For: Glioblastoma Multiforme; Recurrent Glioblastoma
Sites: Birmingham, Alabama; San Diego, California; San Francisco, California · 9 sites in all
- Development of a Soft Robotic Device for Rehabilitation and Assistance of the Upper Limb for People With Neurological DisordersNot yet recruiting
Università Vita-Salute San RaffaeleAcademic, hospital or other
NCT07750314 · 20 participants (planned) · Start Sep 1, 2026 · Primary completion Oct 30, 2026
Device: FRONTIER Soft Exoskeleton · For: Acquired Brain Injury
Sites: Milan, Italy
14 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Frontier", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NKE
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Frontier"[tiab]. The summary above synthesizes these.
- Science's new frontier.
Mertz AF, Mishra A · Science · 2021Editorial
- Neuroimmunology as the next frontier.
Shaker MS, Bernstein JA · Ann Allergy Asthma Immunol · 2023Editorial
- Space: the final frontier?
Levine BD, Nicol ED, Davos CH · Eur J Prev Cardiol · 2022Editorial, Research Support, U.S. Gov't, Non-P.H.S.
- Delirium: The Next Frontier.
Fong TG, Inouye SK · J Gerontol A Biol Sci Med Sci · 2022Research Support, N.I.H., Extramural
- Uterine infertility, the last frontier.
Pirtea P, de Ziegler D, Ayoubi JM · Fertil Steril · 2022Editorial
- Erratum.
Dermatology · 2026Published Erratum
- The next frontier.
Islam S · Br Dent J · 2025News
- The chemistry-glycobiology frontier.
Imperiali B · J Am Chem Soc · 2012Editorial, Introductory Journal Article
- The frontier.
Fryback DG · Med Decis Making · 1988Editorial
- Cardioimmunology: the new frontier!
Sattler S, Campos Ramos G, Ludewig B, et al. · Eur Heart J · 2023
- Computable Quality: The Next Frontier.
Krumholz HM · J Am Coll Cardiol · 2025Editorial
- Medicine in the Final Frontier.
Antonsen E, Fogarty J, Menon A, et al. · Wilderness Environ Med · 2025Editorial
Other devices of this type
Also filed under product code NKE.
- Stratos Lv/Lv-T Cardiac Resynchronization Therapy Pacemaker (Crp-T) SystmeBiotronik, Inc. · PMA 2015
- Anthem, Allure/RF, Allure Quadra/RF family of CRT-PsAbbott Medical · PMA 2026
- Frontier/ Frontier II /Anthem Family of Crt-P'sAbbott Medical · PMA 2014
- Stratos LV CRT-P and Stratos LV-T CRT-PBiotronik, Inc. · PMA 2021
- Consulta Crt-P, Syncra Crt-P, Viva CRT-PMedtronic, Inc. · PMA 2016
- Corox OTW BPBiotronik, Inc. · PMA 2019
- Invive, Intua, Visionist, ValitudeGuidant Corp. · PMA 2017
- Pacemaker ICD CRT Non Implanted ComponentsBiotronik, Inc. · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.